VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Males and females ≥ 18 years old                   │ Males and females ≥ 18 years old                   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinical diagnosis of type 1 diabetes for at least │ Clinical diagnosis of type 1 diabetes for at least │     100 │
│ one year                                           │ one year                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ The subject will have been on insulin pump therapy │ The subject will have been on insulin pump therapy │     100 │
│ for at least 3 months and currently using a fast   │ for at least 3 months and currently using a fast   │         │
│ actin insulin analog (Lispro, Aspart or Guilisine) │ actin insulin analog (Lispro, Aspart or Guilisine) │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Last (less than 3 months) HbA1c ≤ 10%              │ Last (less than 3 months) HbA1c ≤ 10%              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Currently using carbohydrate counting as the meal  │ Currently using carbohydrate counting as the meal  │     100 │
│ insulin dose strategy                              │ insulin dose strategy                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Clinically significant microvascular               │ Clinically significant microvascular               │     100 │
│ complications: nephropathy (estimated glomerular   │ complications: nephropathy (estimated glomerular   │         │
│ filtration rate below 40 ml/min), neuropathy       │ filtration rate below 40 ml/min), neuropathy       │         │
│ (especially diagnosed gastroparesis) or severe     │ (especially diagnosed gastroparesis) or severe     │         │
│ proliferative retinopathy as judged by the         │ proliferative retinopathy as judged by the         │         │
│ investigator                                       │ investigator                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ongoing pregnancy                                  │ Ongoing pregnancy                                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe hypoglycemic episode within 1 month of      │ Severe hypoglycemic episode within 1 month of      │     100 │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Agents affecting gastric emptying (Motilium®,      │ Agents affecting gastric emptying (Motilium®,      │     100 │
│ Prandase®, Victoza®, Byetta® and Symlin®) as well  │ Prandase®, Victoza®, Byetta® and Symlin®) as well  │         │
│ as oral anti-diabetic agents (Metformin, SGLT-2    │ as oral anti-diabetic agents (Metformin, SGLT-2    │         │
│ inhibitors and DPP-4 inhibitors) if not at a       │ inhibitors and DPP-4 inhibitors) if not at a       │         │
│ stable dose for 3 months. Otherwise, these         │ stable dose for 3 months. Otherwise, these         │         │
│ medications are acceptable and will be kept stable │ medications are acceptable and will be kept stable │         │
│ during the entire protocol                         │ during the entire protocol                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Oral steroids unless patients present a low stable │ Oral steroids unless patients present a low stable │     100 │
│ dose (e.g. 10 mg or less of prednisone per day or  │ dose (e.g. 10 mg or less of prednisone per day or  │         │
│ physiological doses, less than 35 mg/day, of       │ physiological doses, less than 35 mg/day, of       │         │
│ hydrocortisone Cortef®). Inhale steroids at stable │ hydrocortisone Cortef®). Inhale steroids at stable │         │
│ dose in the last month are acceptable              │ dose in the last month are acceptable              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other serious medical illness likely to interfere  │ Other serious medical illness likely to interfere  │     100 │
│ with study participation or with the ability to    │ with study participation or with the ability to    │         │
│ complete the trial by the judgment of the          │ complete the trial by the judgment of the          │         │
│ investigator (e.g. unstable psychiatric condition) │ investigator (e.g. unstable psychiatric condition) │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Failure to comply with team's recommendations      │ Failure to comply with team's recommendations      │     100 │
│ (e.g. not willing to change pump parameters,       │ (e.g. not willing to change pump parameters,       │         │
│ follow algorithm's suggestions, etc)               │ follow algorithm's suggestions, etc)               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Recent (\< 3 months) acute macrovascular event     │ Recent (< 3 months) acute macrovascular event e.g. │      99 │
│ e.g. acute coronary syndrome or cardiac surgery    │ acute coronary syndrome or cardiac surgery         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Living or planned travel outside Montreal (\> 1h   │ Living or planned travel outside Montreal (> 1h of │      99 │
│ of driving) area during closed-loop procedures     │ driving) area during closed-loop procedures        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                    │   Score │
╞═══════════════════════════════════╪══════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Males and females ≥ 18 years old │      52 │
╘═══════════════════════════════════╧══════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 96.66666666666667
OverAll Ratio: 97.83333333333334
